1. Working with journals Laura Gallagher, Imperial College London [email_address]

10. Aaarrgghh moments Journal contact has no way of knowing when the study will appear Study is published online as soon as it’s accepted Author contacts you two weeks after publication

12. Thank you [email_address] @ImperialSpark

13. Rachel Twinn Press Officer

14. Nature Publishing Group JOURNAL PRESS RELEASE SENT EMBARGO Nature Thursday PM Wednesday 1800 Research journals Tuesday PM Sunday 1800 Nature Communications Thursday AM Tuesday 1600 Society titles Ad hoc Set by journal

15. Dear Author, Your paper ‘«Title»’ has now been scheduled for Advance Online Publication (AOP) on www.nature.com/nature on «Publication» at 1800 London time / 1300 US Eastern time . The embargo will lift at this time. Please forward this information to any co-authors. Papers published online before they have been allocated to a print issue will be citable via a digital object identifier (DOI) number. The DOI for your paper will be 10.1038/nature «DOI» . Once the paper is published electronically, the DOI can be used to retrieve the abstract and full text from the Nature web site (abstracts are available to everyone, full text only to subscribers) by adding it to the following URL: http://dx.doi.org/ . A week before publication, Nature distributes a press release highlighting papers of general interest. Journalists are given the name of the author(s) to contact, together with phone and e-mail addresses. At this time, journalists are also given online access not only to the papers on the press release but to all the papers due to appear. This means that your work could well receive media interest even if not featured on the press release. You are free to discuss your paper with the media, but we ask you to do this no more than a week before the publication date, and to ensure that Nature ’s embargo conditions are understood by journalists and others. Nature reserves the right to halt the consideration or publication of a paper if these conditions are broken. Journalists are permitted to show papers to independent specialists a few days in advance of publication, under embargo conditions, solely for the purpose of commenting on the work described. Wire services stories must always carry the embargo time at the head of each item, and may not be sent out more than 24 hours before that time. Journalists should seek to credit the relevant Nature publication as the source of stories covered. If you need further clarification about anything related to publicity, please contact one of the Nature offices, as indicated below. From North America Neda Afsarmanesh, Nature New York Tel: +1 212 726 9231; E-mail: [email_address] For Japan, Korea, China, Singapore and Taiwan Mika Nakano, Nature Tokyo Tel: +81 3 3267 8751; E-mail: [email_address] For the UK/Europe/other countries not listed above Rachel Twinn, Nature London Tel: +44 20 7843 4658; E-mail [email_address] For any queries concerning proofs or corrections, please contact the Editorial Production department in London. Yours sincerely, Rachel Twinn Nature Press Office Tel: +44 207 843 4658 Fax: +44 207 843 4951 E-mail: r.twinn@nature.com

16. Dear Colleague, I am writing to inform you that “«Title»” by «Name» has been scheduled for Advance Online Publication (AOP) on www.nature.com at 1800 London time / 1300 US Eastern time on «Publication» . If you wish to see the paper, the author(s) should be able to provide you with a copy, and also to confirm that this title (taken from an early proof of the paper) remains unaltered. You are receiving this letter because one or more of the authors are affiliated to your institution and/or because your organization provided funding for the research. The full listing of authors and their affiliations for this paper is as follows: «Authors» The following funding acknowledgements from the authors appear at the end of the paper: «Funders» The introduction of regular AOP means that selected papers will be subedited and formatted and then published online as soon as they are ready. Papers published online before they have been allocated to a print issue will be citable via a digital object identifier (DOI) number. The DOI for the above paper will be 10.1038/nature«DOI» . Once the paper is published electronically, the DOI can be used to retrieve the abstract and full text from the Nature web site (abstracts are available to everyone, full text only to subscribers) by adding it to the following URL: http://dx.doi.org/ . Embargoes for papers published in this way will lift at the time of electronic publication A week before publication Nature distributes a press release highlighting papers of general interest. Journalists are given the name of the author(s) to contact, together with phone numbers and e-mail addresses. At this time, journalists are also given online access not only to the papers on the press release but to all the papers due to appear. We would be delighted to cooperate with you in ensuring maximum publicity for this paper. We request, however, that you do not send out your own publicity more than a week ahead of electronic publication, as we have found that excessively early publicity can jeopardize an embargo. Please do not post to third-party internet journalist resource sites (such as EurekAlert or AlphaGalileo) until 48 hours before publication. Wire services stories must always carry the embargo time at the head of each item, and may not be sent out more than 24 hours before that time. Journalists should seek to credit the relevant Nature publication as the source of stories covered. It would be helpful if you could make these conditions clear in your own publicity, as well as expressing 1800 London time / 1300 US Eastern Time in your own local time. Authors are free to discuss their paper with the media, but we ask them to do this no more than a week before the publication date, and to ensure that Nature ’s embargo conditions are understood by journalists and others. Journalists are permitted to show papers to independent specialists a few days in advance of publication, under embargo conditions, solely for the purpose of commenting on the work described. Nature reserves the right to halt the publication of a paper if these conditions are broken. If further clarification is required, please consult our embargo policy on the web, http://www.nature.com/author/embargo.html , or contact one of the Nature offices, as indicated below: For North America and Canada Neda Afsarmanesh, Nature New York Tel: +1 212 726 9231; E-mail: [email_address] For Japan, Korea, China, Singapore and Taiwan Mika Nakano , Nature Tokyo Tel: +81 3 3267 8751; E-mail: [email_address] For the UK/Europe/other countries not listed above Rachel Twinn, Nature London Tel: +44 20 7843 4658; E-mail [email_address]

18. When it works well Genetics: Genetic variants associated with schizophrenia *PRESS BRIEFING* [1] DOI: 10.1038/nature08185 [2] DOI: 10.1038/nature08186 [3] DOI: 10.1038/nature08192 Three papers in Nature this week provide new insights into genetic variation and schizophrenia risk. Using combined data from three large cohorts, the papers jointly reveal significant associations to individual loci that implicate immunity, cognition and brain development. Additionally, one of the papers provides genetic evidence for a substantial polygenic component to risk of schizophrenia that also contributes to risk of bipolar disorder. Pamela Sklar and the International Schizophrenia Consortium show that common genetic variation underlies risk of schizophrenia. Their study identifies common variants within the major histocompatibility complex (MHC) locus, and provides molecular genetic evidence for a substantial polygenic component to risk of schizophrenia that involved thousands of common alleles of very small effect. These alleles of small effect also contribute to risk of bipolar disorder. Kari Stefansson and colleagues present a genome-wide association of single nucleotide polymorphisms (SNPs) and reveal significant associations to individual loci that implicate immunity, brain development, memory and cognition in predisposition to schizophrenia. Pablo Gejmans and the Molecular Genetics of Schizophrenia use a case-control study design to show an association between the MHC genomic locus and schizophrenia. Their results suggest a possible involvement of chromatin proteins in this disorder. Together, by using meta-analysis of almost 10,000 cases and 20,000 controls, these three studies indicate that although common genetic variation that underlies risk to schizophrenia can be identified, there are probably few or no single common loci with large effects. CONTACT Pamela Sklar (Massachusetts General Hospital, Boston, MA, USA) Author paper [1] Tel: +1 617 726 0475; E-mail: [email_address] Kari Stefansson (DeCODE Genetics, Regykjavik, Iceland) This author can be contacted through: Edward Farmer (Media Relations, DeCODE Genetics, Regykjavik, Iceland) Author paper [2] Tel: +44 779 601 0107; E-mail: [email_address] Pablo Gejman (NorthShore University HealthSystem Research Institute, Evanston, IL, USA) Author paper [3] Tel: +1 224 364 7550; E-mail: [email_address] Please note a press briefing related to these papers will be held UNDER STRICT EMBARGO at the World Conference of Science Journalism in London on Wednesday 01 July at 0930 London time (BST). Pablo Gejman, David Collier and Mick O’Donovan will discuss the significance of the findings, followed by a Q&A session. A recording of the briefing should be available to download from the press site after the event.